BIT Analytical Instruments and DRG Diagnostics Unveil First Hybrid Analyzer

BIT Analytical Instruments and DRG Diagnostics GmbH have partnered to create the first hybrid analyzer - a fully-automated, random-access analyzer for immunoassays and clinical chemistry. This innovative and unique technology allows, for the first time, the simultaneous measurement of immunoassays and clinical chemistry parameters including turbidimetric tests in one work routine. BIT provided the technology concept, developed the core product idea and design through to engineering, prototype, validation and final production.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Schwalbach, Germany (PRWEB) June 27, 2012

BIT Analytical Instruments (http://www.BIT-Companies.com), a complete contract product development, manufacturing services as well as after-sales service provider to medical and industrial instrument OEM clients, has partnered with DRG Diagnostics to launch a revolutionary new product – the DRG:HYBRID XL Analyzer, a fully-automated and integrated random-access analyzer for immunoassays and clinical chemistry. This innovative and unique technology allows, for the first time, the simultaneous measurement of immunoassays and clinical chemistry parameters including turbidimetric tests in one work routine.

The DRG:HYBRID XL fully-automated analyzer is ideal for small and medium-sized labs. However, it is also suitable for high-workload laboratories performing special routine and niche parameters automatically. The analyzer is flexible enough to measure 40 different tests from one sample or just one or two tests from 20 samples. Additionally, the unique concept of the DRG:HYBRID XL allows each user to combine individual diagnostic panels from immunoassays and clinical chemistry. Following the system requirements defined by DRG, BIT Companies provided the hybrid technology concept, working in cooperation with designers to develop the core product idea and industrial design through to engineering, prototype, validation and final production. We are excited about the full product launch of the HYBRID XL Analyzer by DRG. Further information on DRG and full details and photos can be found on DRG’s website (http://www.drg-diagnostics.de/65-1-Equipment+DRGHYBRiDXL.html).

BIT Companies will feature this new technology at the 2012 annual meeting of the American Association of Clinical Chemistry (Booth #937) in Los Angeles, CA, USA July 15-19.

For over 35 years BIT Companies (http://www.BIT-Companies.com) have provided services in the field of contract development and manufacturing as well as after-sales service for customers in the fields of medical, diagnostics, life science, and biotechnology. As a part of the financially strong Messer Group, BIT Companies provide their systems solutions worldwide and in compliance with ISO 13485 and 9001 standards. As registered contract service providers to the FDA, BIT Companies meet the stringent regulations with regard to medical and complex medical technical products while simultaneously adhering to predefined design-to-cost and time-to-market targets.

BIT Companies (http://www.BIT-Companies.com) include BIT Medtech in San Diego, CA, USA; Source Scientific, LLC in Irvine, California, USA; BIT Analytical Instruments Ltd.in Ludlow, Massachusetts USA; BIT Analytical Instruments GmbH in Schwalbach, Germany; BIT Technologies in Kunshan, China; BIT Japan Ltd. in Tokyo Japan; and BIT C2 Diagnostics in Montpellier, France.